Federal award
EXELAN PHARMACEUTICALS INC
SPE2D219D0070
Contract vehicle (IDV)IDV: ceiling is not spending
Obligated and Ceiling
- Obligated (net)
- $0.00
- Vehicle ceiling (not spending)
- $45,158,494.05
- Current value
- —
- Gross positive obligations
- $0.00
Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.
Award Details
- Recipient
- EXELAN PHARMACEUTICALS INC · FYZXNHSQTMG8
- Owner company
- Not a reviewed companyNo reviewed company owns this recipient.
- Reported parent
- CIPLA USA INC. · MVGMCHRNA7M8
- Awarding agency
- Department of Defense · sub-agency 97AS · office SPE2D2
- Funding agency
- Department of Defense · sub-agency 97AS
- Product or service (PSC)
- 6505 · DRUGS AND BIOLOGICALS
- Industry (NAICS)
- 325411 · MEDICINAL AND BOTANICAL MANUFACTURING
- PIID
- SPE2D219D0070
- Award type code
- B
- Actions
- 12 · May 29, 2019 to May 21, 2024
- Why it is listed
- contract vehicle (IDV)
Action History12
| Date | FY | Mod | Action type | Obligation | Company in company totals |
|---|---|---|---|---|---|
| May 21, 2024 | FY2024 | P00011 | D | $0.00 | — |
| Aug 8, 2023 | FY2023 | P00010 | M | $0.00 | — |
| Jul 10, 2023 | FY2023 | P00009 | D | $0.00 | — |
| May 5, 2023 | FY2023 | P00008 | G | $0.00 | — |
| May 25, 2022 | FY2022 | P00007 | G | $0.00 | — |
| May 19, 2022 | FY2022 | P00005 | G | $0.00 | — |
| May 19, 2022 | FY2022 | P00006 | G | $0.00 | — |
| May 6, 2021 | FY2021 | P00004 | G | $0.00 | — |
| Aug 10, 2020 | FY2020 | P00003 | G | $0.00 | — |
| May 11, 2020 | FY2020 | P00002 | G | $0.00 | — |
| Feb 4, 2020 | FY2020 | P00001 | M | $0.00 | — |
| May 29, 2019 | FY2019 | 0 | — | $0.00 | — |
Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.